Artiva Biotherapeutics, Inc.
ARTV
$2.47
$0.020.82%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -- | -- | -74.62% | -26.63% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -- | -- | -74.62% | -26.63% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -100.00% | -- | -- | -74.62% | -26.63% |
| SG&A Expenses | 56.30% | 73.06% | -4.98% | -8.17% | 3.69% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.56% | 15.71% | 5.67% | -21.06% | 38.64% |
| Operating Income | -52.61% | -269.60% | -36.92% | 18.07% | -45.89% |
| Income Before Tax | -34.96% | -254.91% | -58.13% | 16.47% | -37.88% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -34.15% | -254.91% | -58.13% | 16.47% | -37.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -34.15% | -254.91% | -58.13% | 16.47% | -37.88% |
| EBIT | -52.61% | -269.60% | -36.92% | 18.07% | -45.89% |
| EBITDA | -55.18% | -255.78% | -38.11% | 18.73% | -43.10% |
| EPS Basic | 95.55% | -106.61% | -56.11% | 18.11% | -30.28% |
| Normalized Basic EPS | 95.28% | -106.61% | -56.12% | 18.11% | -30.28% |
| EPS Diluted | 95.54% | -157.07% | -56.11% | 18.11% | -30.28% |
| Normalized Diluted EPS | 95.28% | -157.12% | -56.12% | 18.11% | -30.28% |
| Average Basic Shares Outstanding | 2,912.80% | 2,242.48% | 1.29% | 2.00% | 5.84% |
| Average Diluted Shares Outstanding | 2,912.80% | 171.23% | 1.29% | 2.00% | 5.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |